{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T04:27:32Z","timestamp":1783744052076,"version":"3.55.0"},"reference-count":76,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,3,28]],"date-time":"2018-03-28T00:00:00Z","timestamp":1522195200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2018.00631","type":"journal-article","created":{"date-parts":[[2018,3,28]],"date-time":"2018-03-28T06:24:21Z","timestamp":1522218261000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Targeting Sphingosine Kinase Isoforms Effectively Reduces Growth and Survival of Neoplastic Mast Cells With D816V-KIT"],"prefix":"10.3389","volume":"9","author":[{"given":"Geethani","family":"Bandara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Mu\u00f1oz-Cano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Araceli","family":"Tob\u00edo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzhi","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirsh D.","family":"Komarow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avanti","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean D.","family":"Metcalfe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Olivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,3,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/nrc2875","article-title":"Sphingosine 1-phosphate and cancer","volume":"10","author":"Pyne","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"B2","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0090-6980(01)00108-3","article-title":"Sphingosine kinase: a mediator of vital cellular functions","volume":"64","author":"Olivera","year":"2001","journal-title":"Prostaglandins"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.prostaglandins.2008.02.005","article-title":"Unraveling the complexities of sphingosine-1-phosphate function: the mast cell model","volume":"86","author":"Olivera","year":"2008","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"B4","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.bbalip.2012.06.007","article-title":"Shaping the landscape: metabolic regulation of S1P gradients","volume":"1831","author":"Olivera","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"B5","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/nrm1103","article-title":"Sphingosine-1-phosphate: an enigmatic signalling lipid","volume":"4","author":"Spiegel","year":"2003","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2828","DOI":"10.1182\/blood.V98.9.2828","article-title":"Sphingosine 1-phosphate antagonizes apoptosis of human leukemia cells by inhibiting release of cytochrome c and Smac\/DIABLO from mitochondria","volume":"98","author":"Cuvillier","year":"2001","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.yexcr.2015.02.025","article-title":"Revisiting the sphingolipid rheostat: evolving concepts in cancer therapy","volume":"333","author":"Newton","year":"2015","journal-title":"Exp Cell Res"},{"key":"B8","doi-asserted-by":"publisher","first-page":"794","DOI":"10.2174\/187152011797655122","article-title":"Targeting sphingosine-1-phosphate in hematologic malignancies","volume":"11","author":"Stevenson","year":"2011","journal-title":"Anticancer Agents Med Chem"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2744","DOI":"10.1158\/1535-7163.MCT-15-0279","article-title":"The Sphingosine kinase 2 inhibitor ABC294640 reduces the growth of prostate cancer cells and results in accumulation of dihydroceramides in vitro and in vivo","volume":"14","author":"Venant","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"B10","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1097\/01.jnen.0000175329.59092.2c","article-title":"Sphingosine kinase-1 expression correlates with poor survival of patients with glioblastoma multiforme: roles of sphingosine kinase isoforms in growth of glioblastoma cell lines","volume":"64","author":"Van Brocklyn","year":"2005","journal-title":"J Neuropathol Exp Neurol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1002\/ijc.24594","article-title":"Sphingosine kinase 2 deficient tumor xenografts show impaired growth and fail to polarize macrophages towards an anti-inflammatory phenotype","volume":"125","author":"Weigert","year":"2009","journal-title":"Int J Cancer"},{"key":"B12","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1124\/jpet.109.163444","article-title":"Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine kinase-2","volume":"333","author":"French","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1182\/blood-2008-02-138958","article-title":"A selective sphingosine kinase 1 inhibitor integrates multiple molecular therapeutic targets in human leukemia","volume":"112","author":"Paugh","year":"2008","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1124\/jpet.114.219659","article-title":"The apoptotic mechanism of action of the sphingosine kinase 1 selective inhibitor SKI-178 in human acute myeloid leukemia cell lines","volume":"352","author":"Dick","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1080\/15384047.2015.1078949","article-title":"Sphingosine kinase inhibitors decrease viability and induce cell death in natural killer-large granular lymphocyte leukemia","volume":"16","author":"LeBlanc","year":"2015","journal-title":"Cancer Biol Ther"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.TARG-13-C62","article-title":"Phase I trial of ABC294640, a first-in-class sphingosine kinase-2 inhibitor","volume":"12","author":"Thomas","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1158\/1078-0432.CCR-10-2323","article-title":"A phase I clinical trial of safingol in combination with cisplatin in advanced solid tumors","volume":"17","author":"Dickson","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1159\/000315946","article-title":"Mastocytosis","volume":"95","author":"Brockow","year":"2010","journal-title":"Chem Immunol Allergy"},{"key":"B19","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.iac.2014.02.003","article-title":"Diagnostic criteria and classification of mastocytosis in 2014","volume":"34","author":"Akin","year":"2014","journal-title":"Immunol Allergy Clin North Am"},{"key":"B20","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.iac.2014.01.009","article-title":"Molecular defects in mastocytosis: KIT and beyond KIT","volume":"34","author":"Bibi","year":"2014","journal-title":"Immunol Allergy Clin North Am"},{"key":"B21","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.iac.2014.01.002","article-title":"Functional deregulation of KIT: link to mast cell proliferative diseases and other neoplasms","volume":"34","author":"Cruse","year":"2014","journal-title":"Immunol Allergy Clin North Am"},{"key":"B22","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1111\/all.12409","article-title":"The KIT D816V allele burden predicts survival in patients with mastocytosis and correlates with the WHO type of the disease","volume":"69","author":"Hoermann","year":"2014","journal-title":"Allergy"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1002\/cncr.22187","article-title":"Novel approaches in the treatment of systemic mastocytosis","volume":"107","author":"Quintas-Cardama","year":"2006","journal-title":"Cancer"},{"key":"B24","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1182\/blood-2004-12-4617","article-title":"Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412","volume":"106","author":"Growney","year":"2005","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1182\/blood-2005-07-3022","article-title":"PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects","volume":"107","author":"Gleixner","year":"2006","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1111\/ejh.12544","article-title":"Current treatment options in patients with mastocytosis: status in 2015 and future perspectives","volume":"94","author":"Arock","year":"2015","journal-title":"Eur J Haematol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1074\/jbc.M508931200","article-title":"IgE-dependent activation of sphingosine kinases 1 and 2 and secretion of sphingosine 1-phosphate requires Fyn kinase and contributes to mast cell responses","volume":"281","author":"Olivera","year":"2006","journal-title":"J Biol Chem"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.4049\/jimmunol.1201503","article-title":"Usage of sphingosine kinase isoforms in mast cells is species and\/or cell type determined","volume":"190","author":"Dillahunt","year":"2013","journal-title":"J Immunol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"4193","DOI":"10.1182\/blood-2007-09-115451","article-title":"Distinct roles of sphingosine kinases 1 and 2 in human mast-cell functions","volume":"111","author":"Oskeritzian","year":"2008","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","first-page":"16394","DOI":"10.1073\/pnas.0603734103","article-title":"Role of ABCC1 in export of sphingosine-1-phosphate from mast cells","volume":"103","author":"Mitra","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B31","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.immuni.2007.02.008","article-title":"The sphingosine kinase-sphingosine-1-phosphate axis is a determinant of mast cell function and anaphylaxis","volume":"26","author":"Olivera","year":"2007","journal-title":"Immunity"},{"key":"B32","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jim.2017.06.003","article-title":"An optimized protocol for the generation and functional analysis of human mast cells from CD34+ enriched cell populations","volume":"448","author":"Yin","year":"2017","journal-title":"J Immunol Methods"},{"key":"B33","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1182\/blood.V94.7.2333.419k30_2333_2342","article-title":"Demonstration that human mast cells arise from a progenitor cell population that is CD34(+), c-kit(+), and expresses aminopeptidase N (CD13)","volume":"94","author":"Kirshenbaum","year":"1999","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/S0301-472X(03)00112-7","article-title":"Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit","volume":"31","author":"Akin","year":"2003","journal-title":"Exp Hematol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/0145-2126(88)90050-1","article-title":"Establishment of an immature mast cell line from a patient with mast cell leukemia","volume":"12","author":"Butterfield","year":"1988","journal-title":"Leuk Res"},{"key":"B36","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/S0145-2126(02)00343-0","article-title":"Characterization of novel stem cell factor responsive human mast cell lines LAD 1 and 2 established from a patient with mast cell sarcoma\/leukemia; activation following aggregation of FcepsilonRI or FcgammaRI","volume":"27","author":"Kirshenbaum","year":"2003","journal-title":"Leuk Res"},{"key":"B37","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S0022-1759(02)00210-7","article-title":"Determination of protein phosphorylation in Fc epsilon RI-activated human mast cells by immunoblot analysis requires protein extraction under denaturing conditions","volume":"268","author":"Tkaczyk","year":"2002","journal-title":"J Immunol Methods"},{"key":"B38","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1006\/excr.1999.4427","article-title":"An integral membrane green fluorescent protein marker, Us9-GFP, is quantitatively retained in cells during propidium iodide-based cell cycle analysis by flow cytometry","volume":"248","author":"Kalejta","year":"1999","journal-title":"Exp Cell Res"},{"key":"B39","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ymeth.2006.05.004","article-title":"Simultaneous quantitative analysis of bioactive sphingolipids by high-performance liquid chromatography-tandem mass spectrometry","volume":"39","author":"Bielawski","year":"2006","journal-title":"Methods"},{"key":"B40","doi-asserted-by":"publisher","first-page":"52487","DOI":"10.1074\/jbc.M406512200","article-title":"Mice deficient in sphingosine kinase 1 are rendered lymphopenic by FTY720","volume":"279","author":"Allende","year":"2004","journal-title":"J Biol Chem"},{"key":"B41","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1007\/BF00300234","article-title":"Determination of subcutaneous tumor size in athymic (nude) mice","volume":"24","author":"Tomayko","year":"1989","journal-title":"Cancer Chemother Pharmacol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"7498","DOI":"10.1016\/j.bmcl.2010.10.005","article-title":"Development of a sphingosine kinase 1 specific small-molecule inhibitor","volume":"20","author":"Hengst","year":"2010","journal-title":"Bioorg Med Chem Lett"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/j.cellsig.2011.05.010","article-title":"(R)-FTY720 methyl ether is a specific sphingosine kinase 2 inhibitor: effect on sphingosine kinase 2 expression in HEK 293 cells and actin rearrangement and survival of MCF-7 breast cancer cells","volume":"23","author":"Lim","year":"2011","journal-title":"Cell Signal"},{"key":"B44","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.2353\/ajpath.2010.100220","article-title":"High expression of sphingosine 1-phosphate receptors, S1P1 and S1P3, sphingosine kinase 1, and extracellular signal-regulated kinase-1\/2 is associated with development of tamoxifen resistance in estrogen receptor-positive breast cancer patients","volume":"177","author":"Watson","year":"2010","journal-title":"Am J Pathol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1016\/j.cellsig.2016.06.007","article-title":"Recent advances in the development of sphingosine kinase inhibitors","volume":"28","author":"Pitman","year":"2016","journal-title":"Cell Signal"},{"key":"B46","doi-asserted-by":"publisher","first-page":"46832","DOI":"10.1074\/jbc.M306577200","article-title":"Sphingosine kinase 2 is a nuclear protein and inhibits DNA synthesis","volume":"278","author":"Igarashi","year":"2003","journal-title":"J Biol Chem"},{"key":"B47","doi-asserted-by":"publisher","first-page":"10466","DOI":"10.1158\/0008-5472.CAN-07-2090","article-title":"Involvement of sphingosine kinase 2 in p53-independent induction of p21 by the chemotherapeutic drug doxorubicin","volume":"67","author":"Sankala","year":"2007","journal-title":"Cancer Res"},{"key":"B48","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1038\/381800a0","article-title":"Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate","volume":"381","author":"Cuvillier","year":"1996","journal-title":"Nature"},{"key":"B49","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1093\/nar\/30.1.207","article-title":"Gene expression omnibus: NCBI gene expression and hybridization array data repository","volume":"30","author":"Edgar","year":"2002","journal-title":"Nucleic Acids Res"},{"key":"B50","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/nrm.2016.27","article-title":"Non-canonical functions of cell cycle cyclins and cyclin-dependent kinases","volume":"17","author":"Hydbring","year":"2016","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/35103059","article-title":"CHK2 kinase \u2013 a busy messenger","volume":"2","author":"Bartek","year":"2001","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.molcel.2010.09.019","article-title":"The DNA damage response: making it safe to play with knives","volume":"40","author":"Ciccia","year":"2010","journal-title":"Mol Cell"},{"key":"B53","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1093\/jmcb\/mju045","article-title":"CHK2 kinase in the DNA damage response and beyond","volume":"6","author":"Zannini","year":"2014","journal-title":"J Mol Cell Biol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/nrc2251","article-title":"CHK2 kinase: cancer susceptibility and cancer therapy \u2013 two sides of the same coin?","volume":"7","author":"Antoni","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"B55","doi-asserted-by":"publisher","first-page":"3398","DOI":"10.1038\/emboj.2012.191","article-title":"ATM\/ATR checkpoint activation downregulates CDC25C to prevent mitotic entry with uncapped telomeres","volume":"31","author":"Thanasoula","year":"2012","journal-title":"EMBO J"},{"key":"B56","doi-asserted-by":"publisher","first-page":"25485","DOI":"10.1074\/jbc.M803111200","article-title":"Cleavage-mediated activation of Chk1 during apoptosis","volume":"283","author":"Matsuura","year":"2008","journal-title":"J Biol Chem"},{"key":"B57","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/j.cell.2008.03.037","article-title":"Chk1 suppresses a caspase-2 apoptotic response to DNA damage that bypasses p53, Bcl-2, and caspase-3","volume":"133","author":"Sidi","year":"2008","journal-title":"Cell"},{"key":"B58","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.molcel.2005.07.019","article-title":"Genotoxic stress targets human Chk1 for degradation by the ubiquitin-proteasome pathway","volume":"19","author":"Zhang","year":"2005","journal-title":"Mol Cell"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-4614-8289-5_1","article-title":"Gadd45 in stress signaling, cell cycle control, and apoptosis","volume":"793","author":"Salvador","year":"2013","journal-title":"Adv Exp Med Biol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"3071","DOI":"10.18632\/oncotarget.3074","article-title":"Long-term treatment with imatinib results in profound mast cell deficiency in Ph+ chronic myeloid leukemia","volume":"6","author":"Cerny-Reiterer","year":"2015","journal-title":"Oncotarget"},{"key":"B61","doi-asserted-by":"publisher","first-page":"e44543","DOI":"10.1371\/journal.pone.0044543","article-title":"Characterization of isoenzyme-selective inhibitors of human sphingosine kinases","volume":"7","author":"Gao","year":"2012","journal-title":"PLoS One"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1158\/1541-7786.MCR-11-0336","article-title":"Ablation of sphingosine kinase-2 inhibits tumor cell proliferation and migration","volume":"9","author":"Gao","year":"2011","journal-title":"Mol Cancer Res"},{"key":"B63","doi-asserted-by":"publisher","first-page":"e39209","DOI":"10.1371\/journal.pone.0039209","article-title":"Targeting sphingosine kinase 1 in carcinoma cells decreases proliferation and survival by compromising PKC activity and cytokinesis","volume":"7","author":"Kotelevets","year":"2012","journal-title":"PLoS One"},{"key":"B64","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1096\/fj.05-4412fje","article-title":"Loss of sphingosine kinase-1 activates the intrinsic pathway of programmed cell death: modulation of sphingolipid levels and the induction of apoptosis","volume":"20","author":"Taha","year":"2006","journal-title":"FASEB J"},{"key":"B65","doi-asserted-by":"publisher","first-page":"e119","DOI":"10.1038\/cddis.2011.3","article-title":"S1P lyase regulates DNA damage responses through a novel sphingolipid feedback mechanism","volume":"2","author":"Kumar","year":"2011","journal-title":"Cell Death Dis"},{"key":"B66","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1111\/j.1476-5381.2010.01053.x","article-title":"Loss of sphingosine kinase-1 in carcinoma cells increases formation of reactive oxygen species and sensitivity to doxorubicin-induced DNA damage","volume":"162","author":"Huwiler","year":"2011","journal-title":"Br J Pharmacol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1172\/JCI58765","article-title":"Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models","volume":"122","author":"Ma","year":"2012","journal-title":"J Clin Invest"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1172\/JCI63205","article-title":"Chk\u2019ing p53-deficient breast cancers","volume":"122","author":"Schoppy","year":"2012","journal-title":"J Clin Invest"},{"key":"B69","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/sj.onc.1205080","article-title":"Protection of mammalian telomeres","volume":"21","author":"de Lange","year":"2002","journal-title":"Oncogene"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1126\/science.283.5406.1321","article-title":"p53- and ATM-dependent apoptosis induced by telomeres lacking TRF2","volume":"283","author":"Karlseder","year":"1999","journal-title":"Science"},{"key":"B71","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/sj.leu.2402825","article-title":"Telomerase inhibition enhances apoptosis in human acute leukemia cells: possibility of antitelomerase therapy","volume":"17","author":"Nakajima","year":"2003","journal-title":"Leukemia"},{"key":"B72","doi-asserted-by":"publisher","first-page":"5338","DOI":"10.1038\/sj.onc.1206833","article-title":"Activity of a novel G-quadruplex-interactive telomerase inhibitor, telomestatin (SOT-095), against human leukemia cells: involvement of ATM-dependent DNA damage response pathways","volume":"22","author":"Tauchi","year":"2003","journal-title":"Oncogene"},{"key":"B73","doi-asserted-by":"publisher","first-page":"5719","DOI":"10.1038\/sj.onc.1209577","article-title":"Telomerase inhibition with a novel G-quadruplex-interactive agent, telomestatin: in vitro and in vivo studies in acute leukemia","volume":"25","author":"Tauchi","year":"2006","journal-title":"Oncogene"},{"key":"B74","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.cell.2015.02.002","article-title":"Early telomerase inactivation accelerates aging independently of telomere length","volume":"160","author":"Xie","year":"2015","journal-title":"Cell"},{"key":"B75","doi-asserted-by":"publisher","first-page":"ra58","DOI":"10.1126\/scisignal.aaa4998","article-title":"Binding of the sphingolipid S1P to hTERT stabilizes telomerase at the nuclear periphery by allosterically mimicking protein phosphorylation","volume":"8","author":"Panneer Selvam","year":"2015","journal-title":"Sci Signal"},{"key":"B76","doi-asserted-by":"publisher","first-page":"6647","DOI":"10.4049\/jimmunol.166.11.6647","article-title":"Induction of telomerase activity during development of human mast cells from peripheral blood CD34+ cells: comparisons with tumor mast-cell lines","volume":"166","author":"Chaves-Dias","year":"2001","journal-title":"J Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2018.00631\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,13]],"date-time":"2019-10-13T15:26:50Z","timestamp":1570980410000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2018.00631\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,28]]},"references-count":76,"alternative-id":["10.3389\/fimmu.2018.00631"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2018.00631","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,28]]},"article-number":"631"}}